Emcure gets US FDA NAI classification for Kadu facility

Regulatory & Legal View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1426.00

prior close

₹1444.20

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%-1.2% vs market

Pharmaceuticals peers, median of 154sector-0.5%-0.7% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.7

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.1-1.2-0.5-0.7

Next day

-0.1-0.1+0.1-1.0+0.9

-1.5-0.7-0.8-1.7+0.2

-1.6-0.9-0.8-1.8+0.2

-4.1+0.3-4.4-1.0-3.1

-1.8+0.2-2.0-1.0-0.8

+3.9+1.3+2.6-0.7+4.6

15d

+9.0-2.6+11.6-3.9+12.9

+5.2-7.8+12.9-8.3+13.5

+0.3-4.2+4.5-7.6+7.9

+8.0-12.4+20.3-13.6+21.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals has received the Establishment Inspection Report from the US FDA for its manufacturing facility at Kadu, Surendranagar, Gujarat. The US FDA has classified the inspection as No Action Indicated, meaning no adverse observations were made. This follows an inspection previously intimated on October 10, 2025.

Likely market impact

Positive for shareholders. Clean US FDA outcome removes regulatory concerns and supports continued exports to the US market.